Company profile

Asgard Therapeutics company profile

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.

Business identity

Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2018-01-01

Headquarters

Headquarters
Lund, Skane Lan, Sweden
Postal code
221 84
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$39.6M
Last funding
Series A / $32.6M / 2024-03-14
Last equity funding
Series A / $32.6M
Investors
6
Lead investors
5
Founders
3
Articles
21

Founders and investors

Founders

Cristiana PiresFábio RosaFilipe Pereira

Lead investors

Boehringer Ingelheim Venture FundIndustrifondenJohnson & Johnson InnovationNovo HoldingsRV Invest

Investors

Boehringer Ingelheim Venture FundIndustrifondenJohnson & Johnson InnovationNovo HoldingsRV Invest

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.